A major UK-led clinical trial has found that a treatment commonly used to help premature babies breathe offers no benefit for ...

The CDC's Advisory Committee on Immunization Practices (ACIP) has issued new vaccine recommendations affecting RSV and flu ...

Enjoy, and see you soon… A fast-growing group of Americans is turning to what many call the “gray market” for obesity ...

The FDA has given the green light to expand the use of Moderna's vaccine for the treatment of RSV, the virus that causes ...

Enflonsia is an extended half-life RSV fusion glycoprotein neutralizing monoclonal antibody that is designed to provide durable protection through 5 months.

When an RSV vaccine became available for use during pregnancy, it offered a natural experiment between various countries to see how it compared to a one-time antibody injection ...

A medical panel appointed by Health Secretary Robert F. Kennedy Jr. voted Thursday to recommend a new antibody treatment ...

Chicago, June 09, 2025 (GLOBE NEWSWIRE) -- The global respiratory syncytial virus treatment market valued at USD 2,387.2 million in 2024 and is projected to reach USD 8,332.5 million by 2033 ...

A new national guideline provides evidence-based recommendations for diagnosing, treating, and preventing pediatric ...

For the 2025-2026 respiratory viral season, Moderna intends to have mResvia available for both FDA-approved patient populations.

Respiratory syncytial virus (RSV) is a leading cause of acute lower respiratory infections (ALRTIs) in children under five and poses a persistent threat to child health worldwide.